China Pharma (CPHI) vs Pasithea Therapeutics (KTTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed China Pharma (CPHI) over the past year, gaining 63.9% versus a loss of 72.6%. Over five years, KTTA leads with a -99.4% price change compared with -99.8% for CPHI. China Pharma is the larger company by market cap ($18.9 million vs $17.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPHI | KTTA |
|---|---|---|
| Share price | $0.4384 | $0.4787 |
| Market cap | $18.86M | $17.59M |
| 1-day change | -13.00% | -0.48% |
| YTD return | -63.77% | -62.89% |
| 1-year return | -72.60% | +63.94% |
| 5-year return | -99.84% | -99.40% |
| EPS (TTM) | $-0.42 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.14M | — |
| Revenue growth (YoY) | -8.49% | — |
| Net income (latest FY) | $-3.19M | $-20.43M |
| Gross margin | -3.18% | — |
| Operating margin | -78.16% | — |
| Net margin | -76.91% | — |
| 52-week high | $19.19 | $2.06 |
| 52-week low | $0.38 | $0.32 |
| Distance from 52-week high | -97.72% | -76.76% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +526.70% |
| Average volume | 1.60M | 705.64K |
| Shares outstanding | 43.02M | 36.75M |
| Employees | 215 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KTTA has outperformed CPHI by 136.5 percentage points over the past year.
About China Pharma
CPHI stock →China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CPHI vs KTTA FAQ
Which is bigger, China Pharma or Pasithea Therapeutics?
China Pharma (CPHI) is larger, with a market capitalization of $18.86M compared with $17.59M for Pasithea Therapeutics (KTTA).
Which stock has performed better over the past year, CPHI or KTTA?
KTTA returned +63.94% over the past 12 months, compared with -72.60% for CPHI (price return, excluding dividends). Past performance does not predict future results.
Are China Pharma and Pasithea Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.